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Therapeutic Implication of 
miRNA in Human Disease
Andrew Walayat, Meizi Yang and DaLiao Xiao
Abstract
MicroRNAs (miRNAs) are a class of short non-coding RNA molecules 
that are involved in development and diseases. Early studies are focusing on 
the miRNA profile as a biomarker in disease. As discovery of human miRNAs 
increased in the setting of disease, the research focus was gradually shifted 
towards miRNA therapeutic strategy for diagnostic and treatment of disease. 
Increasing evidences suggest that miRNAs are the next important class of anti-
sense therapeutic molecules, which have significant advantage over antisense 
such as siRNAs because miRNAs are naturally occurring endogenous molecules. 
Aberrant alteration of the endogenous miRNAs has been linked to the develop-
ment of certain diseases. Correcting these altered miRNAs by their mimics or 
inhibitors has been developed as potential therapeutic approaches. Some of 
the miRNA-based therapeutics are processed in preclinical and clinical trial 
for treatment hepatitis C, liver cancer, and other diseases. Currently, the major 
focus in the development of miRNA-based therapeutics is how to increase the 
miRNA stability and optimize delivery systems for specific disease with mini-
mal off-target effect. This chapter will first overview the miRNA biogenesis, 
patho- and physiologic function, and regulation of miRNA molecules. Then, we 
discuss the miRNA-based potential therapeutic approaches and implication in 
disease.
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1. Introduction
MicroRNAs (miRNAs) belong to a family of small non-protein-coding RNAs 
with a single strand of 18–25 nucleotides that regulate multiple target genes at the 
post-transcriptional level. Functionally, miRNAs bind to 6–8 bp seed sequences 
in the 3’ Untranslated Region (3’ UTR) of targets mRNA and induce mRNA 
degradation or repression of protein translation. The term “non-coding RNA” is 
commonly defined a group of RNA that does not encode a protein. With a rapid 
advancement of molecular technology, many new classes of noncoding RNA have 
been founded. Among those noncoding RNAs, miRNA has attracted consider-
able attention because its endogenous origin and its role in the regulation of gene 
makes it more likely target for drug discovery and potential biomarker for specific 
disease.
miRNA research is a relatively new topic, with research ranging back for 
the past 25 years; it has its beginnings in its detection in C. elegans in 1993 and 
its detection in humans in 2000 [1]. Their use in transgenic mice in 2005 to 
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eventually efficacy studies of modified inhibitors of miRNAs in primates in 
2010 illustrates the explosion of research surrounding miRNAs in just 5 years. 
There are now over 2000 miRNAs that have been discovered in humans and it 
is believed that they collectively regulate one third of the genes in the genome 
[2]. miRNAs have been linked to many human diseases and are being pursued as 
clinical diagnostics and as therapeutic targets, showing promise in many fields, 
ranging from cancer therapy to cardiac disease, to even suggestions as a poten-
tial biomarker for numerous diseases and treatment responses. This chapter 
will briefly discuss the miRNAs biogenesis, their function, regulation, and 
implication in disease, then discuss the miRNA-based therapeutic strategies, 
their therapeutic implication in diseases, and some of the current clinical trials 
involving miRNAs.
2. miRNA biochemical synthesis
miRNAs are encoded in the genomes (inter or intragenic) and are transcribed 
from genes located in nuclear DNA; however, such genes are not eventually trans-
lated into protein [3]. These transcribed genes are typically longer than the eventual 
gene product miRNA and undergo much post-transcriptional modification between 
initial transcription and the functional miRNA end-product. After initial transcrip-
tion of the DNA sequence, the miRNA sequence contains a reverse-complement 
base pair segment that forms a double stranded RNA hairpin loop. The entire DNA 
transcript, including the double stranded RNA loop, constitute the primary miRNA 
structure (called pri-miRNA). Pri-miRNA is usually several kilobases long and has 
local stem loop structures. The primary transcripts undergo further processing in 
the nucleus. The ribonucleases Drosha and DiGeorge syndrome critical region gene 
8 (DGCR8) complex are mainly involved in the pri-miRNA processing, which is 
cleaved at the stem of the hairpin structure and generates a hairpin intermediate of 
about 70–100 nucleotides, called pre-miRNA.
The pre-miRNA is then transported out of the nucleus to the cytoplasm for 
further processing to become mature miRNA. There are nuclear pore complexes in 
the nuclear membrane where the pre-miRNA can be transported out of the nucleus 
by means of the RanGTP-dependent nuclear transport receptor exportin 5. In the 
cytoplasm, the pre-miRNA is processed by another ribonuclease, Dicer to create 
a mature miRNA. The mature miRNA is a double-stranded miRNA of variable 
length (~18–25 nucleotides). After the generation of mature miRNA duplex by 
Dicer, the miRNA duplex is incorporated into an Ago family protein complex, 
which generates an effector complex. Then one strand of the miRNA is degraded, 
whereas the other strand remains bound to Ago as mature miRNA (guide strand). 
After strand separation, the guide strand or mature miRNA is incorporated into an 
RNA-induced silencing complex (RISC). After loading, the miRNA promotes the 
RISC to its target mRNA and induces mRNA degradation or translational repres-
sion (see Figure 1).
3. Functions of miRNAs
The general function of miRNA is oriented towards gene silencing [3, 4]. miRNAs 
specifically recognize mRNA and downregulate gene expression by one of the two post-
transcriptional mechanisms: (1) translational repression and (2) mRNA cleavage. The 
determinant of the regulatory mechanism process is mainly dependent on the degree of 
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miRNA–mRNA complementarity. If there is a high degree of complementarity between 
the miRNA and mRNA, it will enable the Ago-catalyzed degradation of target mRNA 
sequences through the mRNA cleavage mechanism process. However, if there is a low 
degree of degree of miRNA–mRNA complementarity, a central mismatch will omit 
degradation and promotes the translational repression mechanism.
The exact mechanism for translational repression by miRNA is still not fully 
understood. However, recent studies suggest that, as the miRNA is incorporated 
into a RISC [3, 4], the associated protein silencing complex can either repress 
translational mechanisms typically associated with ribosomal translation, or induce 
deadenylation of the 3′ poly-A protective posttranscriptional mRNA modification, 
thought to be involved in repression via the mRNA 5′ terminal cap. The mechanism 
for mRNA degradation is mainly involved in endonucleolytic cleavage, which is 
facilitated by Argonaute cleavage proteins. It has been shown that when miRNAs 
have a high degree of sequence complementarity, then target mRNA degradation 
processes are facilitated through Ago protein slicer activity [2, 3]. miRNA typically 
binds to the 3′ untranslated region (3’ UTR) in mRNA that follows the translation 
termination codon. The mechanism of miRNA translation inhibition requires par-
tial sequence match, whereas the mechanism of miRNA-mediated mRNA degrada-
tion requires a near-perfect complementary match (see Figure 1).
Figure 1. 
miRNA biogenesis, function, and strategies for miRNA-based therapies. miRNA is transcribed from miRNA gene 
via RNA polymerase II as pri-miRNA and cleaved by Drosha complex in the nucleus. The resulting precursor 
miRNA (pre-miRNA) is exported to the cytoplasm via exportin 5 complex. In the cytoplasm, Dicer complex 
cleaves pre-miRNA to form mature miRNA duplex. The strand is separated and the functional strand is loaded 
into the RISC complex. The function of miRNA is depending on the complementarity of the seed region of mature 
miRNA to the 3’UTR of the target mRNA gene, either undergoing mRNA cleavage or translational repression. 
Strategies for miRNA-based therapies: improving miRNA in disease can be achieved by the following approaches: 
(a) Small molecule miRNA inhibitors can regulate miRNA expression at the transcriptional level. (b) Antisense 
oligonucleotides can bind to the target miRNA and induce degradation effect. (c) The miR-mask oligonucleotides 
are synthetic oligonucleotides complementary to the 3’ UTR target mRNA that compete with endogenous miRNA 
for its target. (d) The miRNA sponges are oligonucleotide constructs with multiple complementary miRNA 
binding sites to the target miRNA. (e) The miRNA mimics are synthetic miRNAs which can restored the 
downregulated miRNA expression. (f) The AAV miRNA vectors are a group of adenovirus-associated vectors that 
have been inserted genes coding for miRNAs and they are used for restoring downregulated miRNA expression.
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4. Regulation of miRNAs
There are multiple levels of regulation of miRNA expression [5]. Those regula-
tory mechanisms mainly include transcriptional and post-transcriptional mecha-
nisms, as well as effects of endogenous and exogenous compounds on the miRNA 
expression.
4.1 Transcriptional regulation
Similar to protein-coding genes, miRNA genes can also be regulated through 
transcription level. The promoters of miRNA genes are controlled by transcrip-
tion factors (TFs). Many TFs regulate miRNA gene expression through positive 
or negative mechanism in a tissue-specific or developmental-specific manner. For 
instance, MYC inhibits expression of tumor suppressor miRNA-15a, which pro-
mote MYC-mediated tumorigenesis [6]. On the other hands, MYC can stimulate 
expression of miR-9 in neuroblastoma cells, resulting in regulation of E-cadherin 
and cancer metastasis [7]. It has shown that p53 enhances the expression of miR-
34 and miR-107 families, which induce cell cycle arrest and apoptosis [8]. In addi-
tion to regulate by TFs, the expression of miRNA can be regulated by methylation 
of the promoter. Most of the miRNA promoter region has certain CpG islands. 
For example, promoter hypermethylation of genes such as miR-132, miR-34b/c, 
miR-218-1/2, and miR33b have been associated with or denote a poor prognosis 
of various cancers [9, 10]. In addition, the changes in DNMT1 and DNMT3b DNA 
methyltransferases lead to alter the miRNAs (miR-148a, miR-34b/c, miR-9 and 
let-7) gene promoter methylation status, resulting in regulation of their gene 
transcription levels [11]. Furthermore, it has reported that miR-210 is highly 
induced by hypoxia in various cancer cell lines [12], whose expression is not only 
regulated by the transcription factors hypoxia-inducible factor-1 (HIF-1), but 
also regulated by DNA demethylation mechanism in neural progenitor cells under 
both normoxia and hypoxia [12].
4.2 Post-transcriptional regulation
Post-transcriptional regulation has emerged as another important mechanism 
in define the miRNA expression pattern, which mainly involves the process-
ing of the miRNA after transcription. On the post-transcriptional level, the 
expression of microRNAs can be downregulated due to changes in the activity 
of key miRNA biogenesis enzymes, such as Dicer and Drosha. Dicer and Drosha 
generally operate in complexes with double-stranded RBP partner (such as TRBP 
and DGCR8). Both the levels and activity of all of these proteins are subject to 
regulate the accumulation of miRNAs. For example, a decrease in TRBP leads 
to Dicer destabilization and pre-miRNA processing defects [9, 13]. In addition, 
recent studies have also demonstrated that post-translational changes in the Ago 
family of protein could cause significant changes in miRNA expression profiles 
[9, 13].
Another important contributor to miRNA levels is the stability of miRNA, which 
depends on the stage of development or cell type involved. It has been discovered 
that some proteins can bind miRNAs and affect their half-life [9, 14]. For example, 
HuR, a member of the ElaV family of RNA-binding proteins has been shown to sup-
press the inhibitory effect of miRNAs [14]. On the other hands, it has been shown 
that overexpression of Argonaute proteins can decelerate miRNA degradation and 
increase miRNA stability [9, 15].
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4.3 Endogenous and xenobiotics regulation
The presence of physiological and pathological conditions have been demon-
strated to regulate miRNA expression. Previous studies have shown that steroid 
hormones can regulate miRNA expression [16, 17]. Treatment with estradiol or 
tamoxifen has been shown significant changes of different miRNAs expressions 
in patients with breast cancer and in various breast cancer cell lines [16, 17]. In 
addition, corticosterone also can directly regulate miRNAs expressions [18]. Rats 
given chronic corticosterone showed significant behavioral disorder associated with 
differential regulation of 26 miRNAs in the rat prefrontal cortex [18]. Off interest-
ing, those altered miRNAs that were modulated by corticosterone have binding sites 
for glucocorticoid receptor element (GRE), which were either simple, composite or 
tethering type within the 1-kb upstream of the transcription start site. These find-
ing suggests that binding with GRE is a common regulatory mechanism of miRNA 
regulation by corticosterone.
In addition to endogenous regulation, xenobiotics can affect miRNA expres-
sion. Increasing evidence from in vivo and in vitro experiments have showed that 
specific carcinogen could differentially alter certain miRNAs expressions [19]. 
Chronic treatment with benzene in mice had showed significant changes in certain 
miRNAs expressions [20]. Aflatoxin B1, a genotoxic carcinogen, has been reported 
that it can affect the profile of miRNA expression in different animal models 
and cell lines [21, 22]. Therefore, miRNAs can serve as biomarkers of toxicity of 
carcinogen agents and may be useful for early cancer diagnosis. Furthermore, 
harmful life styles such as alcohol consumption and tobacco smoking can impair 
miRNAs expressions [23, 24]. Cigarette smoking can change microRNA profile in 
many human organs and induces the change of plasma miRNA expression profiles 
in healthy subjects [25, 26]. It has been reported that 24 miRNAs were up-regulated 
and 11 miRNAs were down-regulated in plasma from smokers [26]. In addition, 
the serum miRNA profiles in nonsmokers, smokers, and lung-cancer patients were 
significantly different [24].
5. Clinical implication of miRNAs
MicroRNAs are becoming well recognized as their expression levels are changed 
in different diseases such as cancer, liver disease, coronary heart ischemic disease, 
and metabolic disease. Some miRNAs are increased, whereas others are decreased 
in a specific disease, creating a signature miRNA pattern that could serve as a 
biomarker or molecular therapeutic target for a particular disease. For example, 
in the case of cancers, the overexpressed miRNAs are commonly considered as 
oncogenes. On the other hand, some of the miRNAs are expressed very low levels 
in certain cancerous cells and usually prevent tumor development. These groups 
of miRNAs are called as tumor suppressor miRNAs. Let-7 is one of these tumor 
suppressor miRNAs [27]. The miRNAs have remarkable potential in the clini-
cal arena because they can be detected in the blood, serum, tissues (fresh and 
formalin-fixed paraffin- embedded), and fine-needle aspirate specimens. Recently, 
novel in situ hybridization techniques have been described to detect miRNAs in 
tissues, which enables direct miRNA and histomorphologic correlation [28]. The 
clinical implications of miRNA use in medicine are present in both diagnostic and 
therapeutic approaches. In miRNA-based diagnostics, miRNA expression profiling 
has been evaluated as a reliable diagnostic biomarker for differentiating between 
normal and tumor specimens [29, 30]. Ali et al. have reported that the expression of 
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let-7c, let-7f, and miR-200c were significantly decreased in pancreas cancer patients 
whereas miR-486-5p and miR-451 were significantly increased in those patients 
compared with the normal people, which suggests that these miRNAs can be served 
as signature biomarkers for pancreas cancer [30]. Additionally, circulating miRNAs 
can be employed in diagnostic strategies to detect for alterations associated with 
either disorder affliction or treatment response. In the miRNA-based therapeutics, 
the miRNA expression is altered in different diseases and it is now feasible to cor-
rect miRNA expression by injecting miRNAs similar to the use of antisense mRNAs 
and RNAi. For example, because the activation of onco-miRNA genes could cause 
development of cancer, artificial antisense miRNAs could be synthesized and used 
to inhibit their targeted miRNAs to treat or prevent the cancer.
6. miRNA therapeutics: strategies
There are at least two main strategies to target miRNA expression for prevention 
and potential treatment of disease. The first strategies is the use of oligonucleotides 
or virus-based constructs to either directly block the expression of a disease-
associated signature miRNA or to directly substitute for the loss of expression of the 
miRNA. The second strategies is indirectly employing drugs to alter miRNA expres-
sion by targeting their transcription and processing. Blocking miRNA expression 
can be achieved by the use of antisense oligonucleotides, miRNA sponges, miRNA-
mask and small RNA inhibitors. Restoring downregulated miRNA expression 
can be achieved by using synthetic miRNA (miRNA mimic) or by inserting genes 
coding for miRNA into viral constructs. At the transcriptional level, small-molecule 
miRNA inhibitors can be employed to prevent the transitions from DNA transcript 
to pri-miRNA and pre-miRNA. Antisense oligonucleotides can be employed at 
the mature miRNA level to induce degradation or revert the mature miRNA into 
a duplex form with the antisense oligonucleotide. At the functional level, miRNA 
masks can bind complementarily to the 3’ UTR region of target mRNA, compet-
ing for bindings with endogenous miRNAs for the specific target. miRNA sponges 
can be employed to bind target miRNA via complementary mRNA binding sites, 
decreasing expression levels of target miRNAs (see Figure 1).
6.1 Antisense oligonucleotides (AMO)
Antisense inhibition of miRNA function has been an important tool for uncov-
ering miRNA biology and potential therapeutics [31]. Synthetic oligonucleotides 
can be used therapeutically when miRNA dysregulation contributes to pathophysi-
ology. These oligonucleotides are known as anti-miRNA oligonucleotides (miRNA 
inhibitors). To improve functional potency and to provide protection against 
nuclease degradation, they are often chemically modified [31, 32]. An ideal modifi-
cation should increase binding affinity to the extent that specificity is compromised 
and should be non-toxic. There are four most common oligonucleotide modifica-
tions: (1) 2’-O-methyl groups, (2) phosphorothioate, (3) locked nucleic acid (LNA) 
anti-miRNA constructs, and (4) N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-
phenylamine (ZEN).
2’-O-methyl groups are the first generation of AMOs. 2’-O-methyl modi-
fications can help AMOs to increase nuclease resistance and facilitate binding 
affinities to miRNA by the addition of an O-methyl group to the 2’-C atom. 
Phosphorothioate, compared to the 2’-O-methyl analogs, bonds at both the 3′ 
and 5′ ends to prevent nuclease degradation, and a 3′ cholesterol tail to help with 
cell uptake [33]. These modifications help the AMO to penetrate into tissues and 
7Therapeutic Implication of miRNA in Human Disease
DOI: http://dx.doi.org/10.5772/intechopen.82738
organs and significantly increase their half-lives in the target tissues. However, 
the first generation of AMOs have relative low potencies to be effective in animal 
model [34]. Second generation AMOs contain other modifications at the 2′ sugar 
position. Locked nucleic acid (LNA) modifications which are bicyclic nucleic acids 
that tether the 2’O to the 4’C via methylene bridge locking sugar into a 3′ endo 
conformation have been shown to have the best binding affinity and nuclease 
resistance. This group of AMO has been widely used in experimental animals 
[35–37]. Currently, the most advanced miRNA targeting therapy is SPC3649 
(miravirsen), which is a locked nucleic acid-modified oligonucleotide antagoniz-
ing miR-122. This is the first miRNA-targeted drug to enter human clinical trials 
[38]. Despite LNA modifications have higher binding affinity, these modifications 
can lead to off-target effects which may cause toxicity in vivo [35]. Recently, a 
new compound called N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine 
(ZEN), when is included at each end of the AMO, led to increased binding affinity 
to the miRNA and inhibited exonuclease degradation. Recent studies have shown 
that this group of AMOs (ZEN-AMOs) have higher potency and less toxicity than 
LNA-AMOs [39].
6.2 miRNA sponges
miRNA sponges are transcripts that contain multiple (typically 4–10 sepa-
rated by a few nucleotides) tandem-binding sites to a miRNA of interest and are 
transcribed from mammalian expression vectors. The use of miRNA sponges in 
mammalian cells was introduced by Ebert and colleagues [40]. miRNA sponges 
have been found to occur naturally as long non-coding RNA in plants and animals. 
Synthetic miRNA sponges are usually plasmid or viral vectors which contain 
tandemly arrayed miRNA binding sites, separated with a small nucleotide spacer 
and inserted into a 3’UTR of the reporter gene driven by an RNA polymerase II 
promoter [40, 41]. miRNA sponges have the ability to inhibit an entire family of 
miRNA by using the common seed sequence, and can therefore inhibit multiple 
miRNAs at once. Some of the endogenous circular RNAs have been founded to 
function as nature miRNA sponges. For example, circRNA7 has been shown to be 
functions as a miRNA sponge for miRNA-7 in the mouse tissues [42]. The authors 
have further demonstrated that the testis-specific circRNA, sex-determining region 
Y (Sry), serves as a miR-138 sponge [42]. These finding suggest that circRNA 
functioning as a miRNA sponge to regulate miRNA expression may be a common 
phenomenon in human and animals.
6.3 miRNA masking
MicroRNA-masking antisense oligonucleotide technology (miR-mask) is 
another strategy for miRNA-based therapeutics. In contrast to miRNA sponges, 
miR-masks consist of single-stranded 2’-O-methyl modified antisense oligonucle-
otides that are fully complementary to the expected miRNA binding site in the 
3’-UTR of target mRNA [43]. A miR-mask does not directly interact with its target 
miRNA but binds to the binding site of that miRNA in the 3’ UTR of the target 
mRNA by fully complementary mechanism. Therefore, the miR-mask blocks the 
access of its target miRNA to the binding site so as to rescue its target mRNA via 
blocking the action of its target miRNA. miR mask is designed to be fully comple-
mentary to the target mRNA sequence of a miRNA, which suggests that the anti-
miRNA action of a miR-mask is gene-specific. The strategy of miRNA masking 
has been used to disrupt miRNA function and involves masking the target site on 
target mRNA using a modified single-stranded RNA complementary to the target 
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sequence [44, 45]. The miRNA-masking method, in which only specific mRNA is 
masked, may lead to more specific and safer therapeutic strategies.
6.4 Small molecule inhibitors
Several drugs may possess the ability to modulate miRNA expression, targeting 
signaling pathways in miRNA biogenesis, ultimate converging on the activation 
of transcription factors involved in the regulation of miRNA encoding genes. 
The first specific molecule founded to be effective for inhibition of miRNA is an 
azobenzene [46]. The authors have demonstrated that the azobenzene can inhibit 
miRNA-21 by inhibiting miRNA-21 precursor in live cells [46]. MicroRNA-21 is 
significantly overexpressed in many types of human cancers, thus miR-21 is a 
potential therapeutic target. Recently, Naro et al. [47] have reported that, using a 
luciferase-based reporter assay, a high-throughput screen of >300,000 compounds 
led to the discovery of a new aryl amide class of small-molecule miR-21 inhibitors. 
Their studies further found that four aryl amide derivatives were very potent and 
selective miR-21 inhibitors [47]. The small molecule miRNA inhibitors are currently 
limited by their relatively low potencies and issues with specificity to a particular 
miRNA, however, they are much easier to deliver and have the promise for develop-
ment of therapeutics.
6.5 miRNA mimics
In addition to miRNA inhibition as a major miRNA therapeutic approach, 
miRNA replacement treatment with miRNA mimics should be another miRNA 
therapeutic approach in disease associated with decreased miRNAs expressions. 
Synthetic miRNA mimics can assume the regulatory role of natural miRNAs. In dis-
eases such as cancer, some tumor suppression-related miRNAs are downregulated. 
Therefore, artificial double-stranded miRNA (miRNA mimic) has been introduced 
to inhibit cancer [48]. Recent studies have reported that miRNA-34 is a master 
regulator of tumor suppression and a well-defined miRNA tumor suppressor [49]. 
It acts on several cancer relevant cellular pathways, including the p53 and wnt/β-
catenin pathways. Down-regulation of miR-34 expression has been found in many 
tumor types, including lung, liver, breast, and colon carcinoma, and treatment with 
miR-34 mimic has been shown to inhibit tumor growth and progression [49, 50]. 
Consequently, miR-34 mimic, the first miRNA replacement therapy, is headed to 
the clinic for treatment of cancer [49, 50]. Replacement of oncosuppressor miRNAs 
with their mimics provides an effective strategy against cancer.
6.6 Viral vectors
Viral vector administration and encoding of miRNAs have been used for various 
therapeutic purposes [51]. A range of viruses can be employed for these purposes, 
including lentiviruses, adenoviruses, and adenoassociated viruses (AAVs). Since 
these vectors do not integrate into the genome, they can be eliminated efficiently with 
minimal toxicity, yet show remarkable efficiency in transferring RNA-encoding vectors 
into the nucleus of mammalian cells, ensuring high expression of miRNA [51]. Previous 
studies have shown that systemic lentivirus delivery of miR-15a/16 reduces lympho-
cytic leukemia progression in a mouse model [52]. In a murine model of muscular 
dystrophy-associated chronic dilated cardiomyopathy [53], intraventricular delivery 
of AAV vectors containing miR-669a induces long-term miR-669a overexpression and 
significantly decreases hypertrophic remodeling, fibrosis, and cardiomyocyte apop-
tosis. Furthermore, it significantly reduces adverse remodeling and enhances systolic 
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fractional shortening of the left ventricle in treated dystrophic mice, without significant 
detrimental consequences on skeletal muscle wastage [53]. Viral vector therapies have 
shown the highest efficacy for delivering miRNA into cells and organs in vitro and 
in vivo. However, their safety and toxicity remains a controversial issue.
7. miRNA therapeutics in disease
miRNAs are abundant in many mammalian cell types and appear to target about 
60% of the genes of humans and other mammals [54]. Many miRNAs are evolu-
tionarily conserved, which implies that they have important biological functions. 
However, growing evidence suggests that alteration of miRNAs expressions plays 
a key role in the development of disease. The signature miRNAs associated with 
disease and their potential therapeutics in the most common diseases are discussed 
in the following sections.
7.1 Therapeutic potential of microRNAs in cancer
Rapidly growing evidence supports that miRNAs play key roles in the pathogen-
esis of cancer and many miRNAs can function either as oncogenes or tumor sup-
pressors [55]. MiRNAs can influence the development, progression, and metastasis 
of cancers [29, 30]. Their functional effect may differ depending on their expres-
sion levels. They have either an oncogenic potential or tumor-suppressor effect 
depending on their downstream impact on target genes and thereby controlling the 
biologic manifestations of cancers. The activity of a lost or down-regulated tumor 
suppressor miRNA can be restored by using miRNA mimics [56]. To date, there are 
some miRNA-based trials for treatment of cancers. For examples, miR-34 is one of 
the tumor suppressor miRNAs and it is significantly downregulated in many kinds 
of cancer [57]. Therefore, a cancer therapy synthetic miR-34 (MRX34) has been 
developed and has entered phase I clinical trial for liver cancer and metastasis from 
other cancers (NCT01829971) [57]. In lung cancer, miR-27a has been reported to 
be a potential targeted therapy for lung cancer [58]. MicroRNA-loaded minicells 
(miR-16-based mimic miRNA) are designed to counteract the loss of the miR-15 
and miR-16 family and are used in clinic trials for small-cell lung cancer and meso-
thelioma [59]. The miR-205BP/S3 is a possible promising therapeutic modality for 
melanoma [60]. Let-7 is well recognized as one of the important tumor suppres-
sors. So re-expression of the tumor-suppressor let-7 is another proposed miRNA 
therapeutic strategy to upregulate tumor-suppressor miRNA by exogenously trans-
fecting with pre-let-7 that led to the inhibition of growth [27]. In addition to tumor 
suppressor miRNAs, some of the miRNAs can be served as oncogenes and used as 
therapeutic targets for cancer. For example, miR-21 is significantly overexpressed 
in many types of human cancers, thus miR-21 is a potential therapeutic target for a 
certain cancer [47].
7.2 Therapeutic potential of microRNAs in liver disease
Numerous studies have demonstrated that alterations in intracellular miRNAs 
correlated with various liver diseases [28, 38, 61]. In the liver, MiR-122 is one of the 
highly abundant miRNAs that affects various genes involved in hepatic cholesterol 
and lipid metabolism, thereby playing a central role in maintaining liver homeostasis 
[61]. Intriguingly, miR-122 is essential to the stability and propagation of hepatitis C 
virus (HCV) [61]. The finding of the role of miR-122 in the HCV replication process 
is one of the best examples of the potential targeted miRNA-based therapeutic 
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approaches. Blocking miR-122 using antisense approaches has reduced HCV replica-
tion in animal model [61]. MiR-122 binds to two closely spaced target sites (S1 and 
S2) in the highly conserved 5′ untranslated region of the HCV genome, thereby 
forming an oligomeric miR-122–HCV complex that protects the HCV genome from 
nucleolytic degradation or from host innate immune responses. Recently, a LNA-
miR-122, known as Miravirsen, has been introduced and demonstrated that it can 
decrease HCV in nonhuman primates with no side effects [62]. Furthermore, in 
clinical trials of Miravirsen (NCT01200420), it has shown that the use of miravirsen 
in patients with chronic HCV genotype 1 infection can induce dose-dependent 
reductions in HCV RNA levels without evidence of viral resistance [61]. This miRNA-
based therapeutics might deliver promising outcomes in the setting of liver disease.
7.3 Therapeutic potential of microRNAs in heart disease
Growing evidence shows miRNAs could be a promise molecular therapeutic 
strategy for cardiovascular disease [63, 64]. Previous studies have demonstrated 
that miRNA-21 level is upregulated in activated fibroblasts of the failing heart [65]. 
The investigators further demonstrated in an in vivo study of a mouse model of 
pressure-overload-induced heart disease that administration of a miRNA-21 anti-
sense construct reduces the extent of heart fibrosis and overall heart function [65]. 
Their findings validate miR-21 as a disease target in heart failure and establish the 
therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular dis-
ease setting. The miR-15 family is also found to be significantly increased in cardiac 
diseases [66]. Knockdown of the miR-15 family with LNA-modified anti-miRNAs 
resulted in reduced infarct size after ischaemia-reperfusion injury [66], suggesting 
it could serve as a therapeutic target for the manipulation of cardiac remodeling and 
function in the setting of myocardial infarction.
Diastolic dysfunction is a major clinical syndrome. Gain- and loss-of-function 
studies in animal model have shown that genetic deletion of the cardiac-specific 
miR-208a prevents pathological cardiac remodeling. Furthermore, therapeutic 
inhibition of miR-208a by subcutaneous delivery of miR-208a antisense during 
hypertension-induced heart failure in rats can prevent pathological myosin switch-
ing and cardiac remodeling and improve cardiac function [67, 68]. These studies 
suggest that miR-208 can serve as a potent therapeutic target for the modulation 
of cardiac function and remodeling during heart disease progression. In addition, 
miRNAs also play an important role in regulation of cardiovascular angiogenesis. 
AntimiR-92a (MRG-110) is currently used as a Phase I clinical trial for Miragen and 
it could offer a potential therapeutic to accelerate the healing process and revascu-
larization in chronic ischemic disease. MRG-110 is being developed under a license 
and collaboration agreement with Servier for the treatment of heart failure and 
other ischemic disease [www.miragen.com]. To date, there is another therapeutics 
miRNA (MGN-5804 which targeting miR-378) in the development phase for the 
treatment of cardiovascular disease.
7.4 Therapeutic potential of microRNAs in renal disease
MicroRNAs can serve as mediators and therapeutic targets in many chronic renal 
diseases [69].
A variety of miRNAs are specifically enriched in the renal tissue as compared 
with other tissues, including miR-192, miR-194, miR-204, miR-215, and miR-216 
[69]. miR-192 is one of the key miRNAs which is involved in diabetic nephropathy 
[70]. The authors reported that, in individual biopsies, tubulointerstitial fibrosis 
and low estimated GFR are associated with a decrease in miR-192 expression [70].
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miR-192 targets E-cadherin, resulting in fibrosis of tubular cells and develop-
ment of diabetic nephropathy. These findings suggests that miR-192 mimics should 
potentially be used as therapeutics of diabetic nephropathy. A global expres-
sion profiling study have shown that miR-21 is one of the most highly regulated 
miRNAs in kidneys of mice with diabetic nephropathy [71]. It has been reported 
that miR-21 antagonism in vitro and in vivo in streptozotocin-induced diabetic 
mice decreased mesangial expansion, interstitial fibrosis, macrophage infiltra-
tion, podocyte loss, albuminuria, and fibrotic- and inflammatory gene expres-
sion, which suggests that therapeutic miR-21 silencing could ameliorate diabetic 
kidney disease. Indeed, in a mouse model of chronic kidney disease, treatment 
with antagomir against miR-21 reverses both glomerular and tubular cell damage, 
resulting in a decrease in renal fibrosis and prolonging the life span of the chronic 
kidney disease-affected mice [72].
7.5 Therapeutic potential of microRNAs in neurological disease
Some of the miRNAs are highly abundant in the nervous system, where they 
play key roles in developmental neurobiology. Numerous studies have shown a 
dysregulation of miRNAs in neurological disease [73, 74]. These alterations in 
miRNAs expression prior to the onset of or during the course of disease pathology 
raises the possibility that expressing or inhibiting specific miRNAs might amelio-
rate the disease process and provide an effective therapeutic strategy. For example, 
Alzheimer’s disease (AD) is being tested for potential miRNA-based therapy 
[75]. It has reported that a member of the miR-15/107 superfamily, miR-16 can 
specifically inhibits the expression of AD biomarkers Aβ and Tau, as well as brain 
inflammation and oxidative stress. MicroR-16 mimics delivered into the brain of 
mice resulted in a reduction of AD-related genes expression in a region-dependent 
manner, thus supporting the potential of miR-16 as an excellent therapeutic 
candidate for treatment of Alzheimer’s disease. Similar to the changes of miRNAs 
in Alzheimer’s disease, numerous miRNAs in human and animal models are also 
reported to be dysregulated in Parkinson’s disease [76]. Some of these dysregulated 
miRNAs have been suggested to be potential therapeutic targets for Parkinson’s 
disease. For example, Cho et al. had suggested that overexpression of miR-205 
by miR-205 mimic could provide a potential therapeutic strategy to suppress the 
abnormal upregulation of LRRK2 protein in Parkinson’s disease [77]. In addi-
tion, it has been reported that early downregulation of miR-34b/c in Parkinson’s 
disease triggers downstream transcriptome alterations underlying mitochondrial 
dysfunction and oxidative stress, which ultimately compromise cell viability [78]. 
Therefore, upregulation of miR-34b/c may be an applicable therapeutic strategy for 
Parkinson’s disease.
8. Future prospects
As the miRNA field dramatically grows, a better understanding of miRNA bio-
genesis and path-physiologic function will help to develop miRNA-based therapies. 
In addition, it is well known that a specific miRNA could target multiple genes and 
affect different organs in the same time. Therefore, research efforts should try to 
maximize the benefit of target diversity and prevent off-target effects. To achieve 
this goal, improvement of the chemical design of miRNA antisense and mimics and 
developing novel delivery systems are very important to ensure that the desired 
miRNA concentrations are achieved in organs and the targets are specifically 
regulated.
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The use of synthetic miRNAs holds great promise as a new class of potential thera-
peutic agents by silencing the gene(s) of interest. Applicable to a wide variety of human 
diseases such as cancer, viral infections, genetic disorders, and cardiovascular disease, 
the attractiveness of miRNA therapeutics is their ability to target specific genes of inter-
est, not always possible with small molecules or protein-based drugs. When designing 
drugs for therapeutic use, RNA sequence must be carefully designed to avoid undesired 
effects and immune responses in the body. The care into making a safe and relevant 
delivery system for miRNA-based therapies must also balance considerations of target 
tissue and cell delivery, cellular uptake, and nuclease degradation of the molecule.
Although a considerable number of clinical trials involving miRNA therapeutics 
have been conducted over the years, not all of those miRNA therapeutics have so far 
moved into clinical implication. The big challenges for miRNA-based therapeutics 
is to identify the best miRNA candidates or miRNA targets for each type of disease. 
The other challenges include the optimizing the miRNA delivery vehicles that can 
have higher targeting specificity and stability, as well as having lower toxicities and 
off-target effects. Although there are still hurdles to the use of mRNA-targeting 
approaches for clinical applications, with the rapid expansion occurring in this 
field, the prospects of miRNA-based therapeutics remain promising.
9. Conclusions
Growing evidences have shown that miRNAs play a key role in biological 
function and cell homeostasis. If the miRNAs are dysregulated, they lead to the 
 development of many disease phenotypes. The miRNAs have immense potential 
in the clinical arena because they can be detected in the blood, serum, tissues, and 
fine-needle aspirate specimens. In addition, the discovery of miRNAs and their 
expression profile in a wide variety of diseases has led investigators to understand 
the key role of miRNAs as biomarkers during disease progression. Furthermore, 
because the miRNAs are relatively small size and they can regulate the network 
of target genes, they are promising targets for therapeutics. The most attractive 
feature of miRNA-based therapy is that a single miRNA could be useful for target-
ing multiple genes that are deregulated in disease, which can be further investigated 
through systems biology and network analysis that allows designing disease-specific 
personalized therapy. In summary, miRNAs are poised to provide diagnostic, prog-
nostic, and therapeutic targets for several diseases. As the field continues to grow, 
miRNA-based therapeutics may develop a novel class of drugs for different diseases.
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